# Hims & Hers Health (HIMS) — InvestMoat Analysis

_Last analyzed: September 25, 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/hims_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 54 |
| Growth trajectory | 73 |
| Valuation | 76 |
| **Composite** | **67** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** HIMS
- **Market Cap:** ~$7.4B

## Moat

DTC telehealth subscription brand with vertical pharmacy and multi-category bundle — narrow brand moat. March 2026 Novo Nordisk branded GLP-1 partnership resolved the compounding lawsuit overhang but compressed weight-loss unit economics; July 2026 FTC privacy/billing suit re-opens regulatory tail risk.

### The DTC Telehealth Brand Moat

Hims's moat is **brand recognition + vertical pharmacy + multi-category subscription bundling** in telehealth — real but narrow, with regulatory exposure now centred on FTC consumer-protection claims and branded-GLP-1 margin mix rather than compounded-semaglutide enforcement alone:

- **DTC Brand Reach in Targeted Categories:** Hims has built genuine brand awareness in men's hair loss, sexual health, mental health, weight-loss, and women's hormonal health. The marketing flywheel and CAC-LTV economics in established categories remain the franchise's core; Q1 subscribers reached 2.58M (+9% YoY) even as U.S. revenue dipped on the GLP-1 mix shift.
- **Vertical Pharmacy and Branded GLP-1 Access:** Hims operates its own compounding pharmacies, but the March 2026 Novo Nordisk collaboration put FDA-approved Ozempic and Wegovy (injectable and oral) on the platform at Novo self-pay prices and ended Novo's patent suit. Compounded GLP-1 is now limited to clinically necessary cases — a cleaner legal channel at structurally lower margin than 2024 compounded semaglutide.
- **Clinical Network and International Scale:** A national provider network plus ZAVA, Livewell, and the June 2026 Eucalyptus close (Australia/Canada/Germany/Japan/UK footprint; ~850K prior customers) extend the closed-loop subscription stack. Switching costs for the patient remain low; convenience-and-pricing UX vs traditional care is the retention lever.

**Moat verdict:** Hims is a brand-and-bundle moat business in a regulated industry — AI is neutral-to-positive on cost (provider productivity) but the dominant moat questions are regulatory (now FTC + compounding history) and competitive. The Novo partnership cleans up GLP-1 legality at the cost of margin; the thesis remains execution-and-category-expansion, appropriately sized as speculative growth.

### Top competitors

- **[Novo Nordisk (NVO)](https://investmoat.com/stocks/nvo):** Sells Wegovy direct to patients through its own channel.
- **[Eli Lilly (LLY)](https://investmoat.com/stocks/lly):** LillyDirect sells Zepbound direct to consumers.
- **Ro:** Private telehealth rival in weight loss and men's health.

## Growth

Q1 revenue $608M (+4% YoY) was a transition print after the branded-GLP-1 pivot; FY26 guide raised to $2.8-3.0B (+19-28%, ex-Eucalyptus) with Adj EBITDA $275-350M (10-12% margin). Q2 guide $680-700M (+25-28% YoY) is the first full quarter of branded weight-loss — results due AMC August 10, 2026 (not yet reported). 2030 targets remain ≥$6.5B revenue / $1.3B Adj EBITDA.

- **Revenue CAGR estimate:** 20-28%
- **Primary type:** TAM expansion
- **Margin trend:** compressing
- **Key risk (high):** If the July 2026 FTC/state privacy-and-billing suit forces a large settlement or advertising restrictions, or if branded GLP-1 gross margin stays near the Q1 65% level without the guided H2 Adj EBITDA ramp toward ~14% margins, FY26 EBITDA misses the $275-350M band and the multiple re-rates toward 1.5× sales.
- **Drivers:**
  - Weight-Loss Category — Branded Novo Wegovy/Ozempic live since late March; Q1 U.S. rev −8% on mix/shipping, Q2 guide implies re-acceleration (stable)
  - Subscriber Growth — 2.58M end-Q1 (+9% YoY); monthly rev/sub $80 (−6% YoY) as mix shifts to branded GLP-1 (stable)
  - International & Category Expansion — RoW rev $78M in Q1 (~10× YoY); Eucalyptus closed June 2026; women's health/testosterone cohorts still ramping (accelerating)
- **Score derivation:** Base 86 (24% midpoint of 20-28%) +1.3 trajectory (international/category accelerating; weight-loss and subscribers stable through the branded pivot) −4 margin (gross margin 65% vs 73% YoY; Adj EBITDA margin guided 10-12% after a 7% Q1) −10 high regulatory/FTC risk = 73. Down from ~81: the old 30-45% CAGR no longer answers to the guided or 2030 series after the compounded-to-branded GLP-1 reset.

## Valuation

At ~$29.30 (September 24, 2026) HIMS trades at ~2.3× FY26 sales on the ~$2.9B guide midpoint, a sharp de-rating from the ~4.5-5× / ~$50 regime in May. The base is trimmed from $42 (~3× sales) to $35 (~2.5× sales) so it sits within ~12% of the ~$31 Street mean target rather than ~34% above it. Spot sits ~33% above the $22 bear and ~16% below base; the multiple prices execution and FTC risk honestly but leaves limited cushion if H2 margins disappoint.

| Multiple | Value | Note |
| --- | --- | --- |
| Price / Sales (FY26) | ~2.5× | ~$7.4B mkt cap / $2.9B guide midpoint |
| EV / Adj EBITDA (FY26) | ~25× | On ~$313M Adj EBITDA midpoint |
| Forward P/E (FY26) | N/M | TTM GAAP EPS negative; Street near-term EPS still volatile |
| Street 12-mo PT | ~$31 | FactSet mean; range roughly $21–$40 |
| FCF (Q1) | $53M | Still FCF-positive through the mix transition |

Valuation has reset with the stock; the equity remains a high-volatility execution-and-regulatory position. Base case assumes the FY26 guide holds and FTC overhang is manageable — not a quality-compounder multiple. _(as of August 10, 2026)_

## Price scenarios

### Bear — $22

FTC suit escalates costs/CAC, branded weight-loss margins stay compressed, FY26 EBITDA misses — multiple compresses toward ~1.5× sales.

- FTC/state action forces material settlement, ad restrictions, or cancellation-UX changes that lift CAC
- Branded Wegovy/Ozempic mix keeps gross margin near mid-60s without H2 operating leverage
- Subscriber growth stalls below ~10% YoY as weight-loss ARPU normalises

### Base — $35

FY26 revenue delivered near guide midpoint, Q2 confirms re-acceleration, Adj EBITDA margin exits toward guide, multiple holds ~2.5× sales.

- Q2–Q4 print inside the $2.8-3.0B / $275-350M bands (plus initial Eucalyptus contribution)
- Weight-loss settles into branded Novo mix with stabilising gross margin
- International (Eucalyptus + ZAVA/Livewell) and new categories reach a meaningful revenue share

### Bull — $68

Hims becomes the leading multi-country DTC chronic-care platform, 2030 path looks credible, Adj EBITDA margin expands toward mid-teens, multiple re-rates toward 4×+ sales.

- Subscriber base scales past 3.5M with improving NRR as diagnostics/personalisation land
- Eucalyptus integration lifts RoW without proportional margin dilution
- FTC resolved without franchise damage; category mix diversifies away from GLP-1 concentration

---

InvestMoat is a research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.